Regeneron Pharmaceuticals, Inc. (REGN) Prepares for $83M Charge
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top stocks to buy in Michael Burry’s stock portfolio.
Regeneron Pharmaceuticals Inc. (REGN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Sigma Advisors John Overdeck And David Siegel | 938,500 | $492,712,500 | +70% | 1.01% |
| 2. | D E Shaw D. E. Shaw | 777,469 | $408,171,225 | +35% | 0.29% |
| 3. | Citadel Investment Group Ken Griffin | 680,505 | $357,265,125 | +809% | 0.06% |
| 4. | Millennium Management Israel Englander | 338,826 | $177,883,650 | +100% | 0.09% |
| 5. | Squarepoint Ops LLC Maxime Fortin (Cio) | 297,691 | $156,287,775 | +5% | 0.16% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $487.01 | 2,557 | $1,245,286.62 | 23,880,537 | 2017-08-25 | Filing | |
| $485.99 | 2,681 | $1,302,949.65 | 23,877,980 | 2017-08-25 | Filing | |
| $485.28 | 5,723 | $2,777,256.30 | 23,875,299 | 2017-08-25 | Filing | |
| $484.21 | 2,000 | $968,420.00 | 23,869,576 | 2017-08-25 | Filing | |
| $482.87 | 4,485 | $2,165,687.20 | 23,867,576 | 2017-08-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $844.61 | 1,000 | $844,610.00 | 12,931 | 2024-11-01 | Filing | |
| $1,059.28 | 2 | $2,118.56 | 17,582 | 2024-10-01 | Filing | |
| $1,057.38 | 2 | $2,114.76 | 17,584 | 2024-10-01 | Filing | |
| $1,056.68 | 3 | $3,170.04 | 17,586 | 2024-10-01 | Filing | |
| $1,054.90 | 3 | $3,164.70 | 17,589 | 2024-10-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 477,810 | $268,658,229 | 0.37% | |
| 2. | 127,536 | $71,709,667 | 0.07% | |
| 3. | 67,300 | $37,840,771 | 3.77% | |
| 4. | 45,195 | $25,411,793 | 0.43% | |
| 5. | 25,873 | $14,547,612 | 0.1% |
News See All
Michael Burry Stock Portfolio: 6 Stocks to Buy
Michael Burry needs no introduction on Wall Street.
Regeneron (REGN) Highlights Benefits of Semaglutide and Trevogrumab in Obesity Management
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the best biotech stocks to buy. On September 17, Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) Draws Attention With Rare Disease Breakthrough
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most promising biotech stocks to buy according to hedge funds.
Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials
On September 17, 2025, Regeneron Pharmaceuticals Inc.
Regeneron's Evkeeza Receives FDA Approval to Treat HoFH in Children Aged 1 to Less Than 5
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best NASDAQ stocks to buy according to hedge funds.
7 Most Promising Biotech Stocks to Buy According to Hedge Funds
If there’s one sector that is gaining popularity each day, it’s definitely the biotechnology market.
14 Best NASDAQ Stocks to Buy According to Hedge Funds
Earlier on August 19, Erik Woodring of Morgan Stanley joined CNBC's 'The Exchange' to discuss the most under-owned tech stocks and what's behind the bifurcation in the sector.
14 Best Biotech Stocks to Buy Right Now
The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.
12 Best Widow and Orphan Stocks to Buy According to Analysts
According to Reuters, U.S. stock index futures increased on September 29.
Hedge Fund Resource Center Billionaire Hedge Funds
